Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 29, 2019
Daily News
November 29, 2019
- Komeito Calls for System to Reward Useful New Indications
November 29, 2019
- Japan Pharma Industry Chief Raises Alarm over Comparator PMP Deduction Proposal: LDP Study Group
November 29, 2019
- Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
- 10-Plus Japan Drug Makers Up FY2019 Guidance on Bullish New Drugs, Mainstays: Tally
November 29, 2019
- Govt Panel to Draw Up New AMR Action Plan for 2021 and Beyond
November 29, 2019
- Rick Kozloski Tapped as President of Alcon Japan
November 29, 2019
- Hisamitsu, Kyowa Kirin Put Off Launch of Haruropi Tape due to Faulty Barcode
November 29, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…